To fund its initiatives to deliver MDMA therapy to marketplace, MAPS General public Advantage Company (PBC) — MAPS’ pharma subsidiary, which bifurcated in 2014 but didn't accept expense in return for equity and will not protected the $70 million needed to move forward — has morphed into your for-earnings Lykos Therapeutics.I st… Read More